ReviewAntipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms
Introduction
Antipsychotics play an important role in the management of patients with schizophrenia in that they are indispensable for not only relieving psychotic symptoms in the acute phase (Leucht et al., 2009a, Leucht et al., 2009b) but also preventing relapse in the maintenance phase (Leucht et al., 2003). Therefore, patients with schizophrenia as a rule undergo long-term antipsychotic treatment in order to maintain stability.
Various guidelines and algorithms have been developed regarding psychopharmacological treatment of schizophrenia in an effort to take advantage of accumulating evidence so that it can be better translated into actual clinical practice. For instance, a recent trial in Germany has shown that guideline implementation increased the rate of antipsychotic monotherapy and decreased the incidence of neurologic side effects in a significant manner (Weinmann et al., 2008). In general, in the acute phase of treatment, guidelines and algorithms do not differ very much in their context (Gaebel et al., 2005, Moore, 2011) since they base their recommendations on the similar evidence that is composed of influential double-blind randomized controlled trials or meta-analyses. However, in contrast to acute treatment, the guidelines and algorithms are more diverse regarding maintenance treatment (Bhanji and Tempier, 2002) because there is less evidence available to base the recommendations. Furthermore, the concept of “maintenance treatment” includes various strategies that could reflect treatment needs in chronic phase of the illness; namely antipsychotic discontinuation, intermittent antipsychotic treatment, and antipsychotic dose reduction.
The purpose of this systematic review is to overview various guidelines and algorithms on psychopharmacological treatment for patients with schizophrenia, to highlight management issues with antipsychotics in the maintenance phase of the illness.
Section snippets
Methods
Guidelines and algorithms for schizophrenia that were published or updated after 2000 were searched, using Medline, PubMed, EMBASE, PsycINFO with the following key words: “guideline(s), algorithm(s)” combined with “schizophrenia/schizophrenic, psychosis/psychotic”. The reference lists of the relevant reports were also examined. Last search was conducted on July 2011. Our literature search was limited to publications in English.
Each guideline or algorithm was first evaluated in terms of
Results
Fourteen guidelines and algorithms were identified; their brief summaries are provided in Table 1.
Discussion
This systematic review evaluated psychopharmacological strategies in the maintenance phase of schizophrenia described in the guidelines and algorithms and represents the first work of this sort to the best of our knowledge. It was firstly found that there has been no explicit consensus on the definitions of maintenance phase (Bhanji and Tempier, 2002), making interpretation of treatment recommendations in that stage complicated. Although it is true that the definition of “acute”,
Role of funding source
None.
Contributors
H.T. conceptualized this review, conducted systematic literature search and first drafted the manuscript (under a supervision of T.S.). All authors have significantly contributed to the subsequent revisions for intellectual input and approved to submit the final version of the manuscript.
Conflict of interest
Dr. Takeuchi has received speaker's honoraria or manuscript fees from Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKlein, Janssen Pharmaceutical, and Otsuka Pharmaceutical within the past 5 years.
Dr. Suzuki has received fellowship grants from the Japanese Society of Clinical Neuropsychopharmacology, Government of Canada Post-Doctoral Research Fellowships, Kanae Foundation and Mochida Memorial Foundation, and manuscript fee from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin, and speaker's
Acknowledgment
None
References (55)
- et al.
High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2006) - et al.
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Lancet
(2009) - et al.
Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study
Eur. Neuropsychopharmacol.
(2008) - et al.
How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review
J. Psychiatr. Res.
(2011) - et al.
Texas Medication Algorithm Project Procedural Manual, Schizophrenia Treatment Algorithms
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
J. Psychopharmacol.
(2011)- et al.
Managing schizophrenia during the stable phase: is there consensus among practice guidelines?
Can. J. Psychiatry
(2002) - et al.
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements
Schizophr. Bull.
(2010) Clinical practice guidelines. Treatment of schizophrenia
Can. J. Psychiatry
(2005)- et al.
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks
Am. J. Psychiatry
(1999)
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
BMJ
The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime
Int. Clin. Psychopharmacol.
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders
J. Clin. Psychiatry
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia
World J. Biol. Psychiatry
Neuroleptic dose reduction in persistently psychotic patients
Hosp. Community Psychiatry
Schizophrenia practice guidelines: international survey and comparison
Br. J. Psychiatry
Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia
J. Clin. Psychiatry
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
Ann. Gen. Psychiatry
Adverse effects of atypical antipsychotics: differential risk and clinical implications
CNS Drugs
Intermittent vs maintenance medication in schizophrenia. Two-year results
Arch. Gen. Psychiatry
Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study
Arch. Gen. Psychiatry
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients
Am. J. Psychiatry
Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia
Br. J. Psychiatry
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years
BMJ
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates
Arch. Gen. Psychiatry
Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view
Psychiatry
Cited by (94)
Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms
2021, Schizophrenia ResearchCitation Excerpt :Moreover, the recommendations even in the same guideline may well be changed over time upon the emergence of new evidence; the guidelines are usually updated on a regular basis. In fact, our 2 previous systematic reviews summarizing clinical guidelines/algorithms in terms of the maintenance treatment of schizophrenia highlighted that the recommendations on antipsychotic discontinuation and reduction were substantially altered during 9 years (Shimomura et al., 2020; Takeuchi et al., 2012). The current systematic review has limitations that should be noted.
You say “schizophrenia” and I say “psychosis”: Just tell me when I can come off this medication
2020, Schizophrenia ResearchThe long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples
2020, Schizophrenia ResearchCitation Excerpt :Additionally, we provide clinical case examples to illustrate the different course types after stepwise drug discontinuation and early intervention in case of early warning signs of an impending relapse (IT). To our knowledge, this is the first up-to-date review focusing on clinical guideline recommendations for long-term antipsychotic treatment in patients diagnosed with schizophrenia (see Takeuchi et al., 2012 for an older review on this topic). We selected six evidence-based guidelines for the treatment of schizophrenia for review.